BF-223
/ BullFrog AI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 26, 2023
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
(GlobeNewswire)
- "BullFrog AI Holdings, Inc...announced positive data in a preclinical study investigating the anti-cancer activity of a novel prodrug of mebendazole for the treatment of glioblastoma...Animals treated with BF-223 had an average survival time of 27.9 days compared with 27.3 days for mice treated with BF-222 and 23.4 days for mice given placebo. Mice treated with BF-223 were administered 80% of the dose that mice treated with BF-222 received, and improved outcomes for both treatment groups were statistically significant compared to placebo. In addition, animals treated with equivalent doses of BF-222 and BF-223 showed comparable and significant reduction in tumor growth compared to control animals during the study."
Preclinical • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1